AllPennyStocks.com BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout

Under the agreement, SK Biopharmaceuticals gets exclusive worldwide rights to Biohaven’s Kv7 platform and its lead once-daily pill, opakalim.

Other Penny Stock Movers

$500 Million AI Merger Sends This Microcap Soaring
Colombian Oil Producer Jumps as Q2 Revenue More Than Doubles
Medtech Developer Surges on Triple-Digit EBITDA Growth
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top